PRNB News and Press, Principia Biopharma Inc. From 05/12/20

SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced an upcoming full data set presentation from the Phase 2 Part B pemphig...

Principia Biopharma (NASDAQ: PRNB ): Q1 GAAP EPS of -$0.99. More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced financial results for the first quarter ended March 31, 2020. ...

SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that management will present at the 2020 Bank of America Health Care C...

SNY is undervalued Since early August last year, the Sanofi ( SNY ) share price has increased almost 20% to its current level of $48.37 at the time of writing. That's still about 7% off the 52-week high, and a fair value is now probably above $58.00 - an increase of about another 20%. This...

Sanofi (NASDAQ: SNY ) announces positive results from a Phase 2b clinical trial evaluating brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor SAR442168 in patients with relapsing forms of multiple sclerosis (MS). More news on: Sanofi, Principia Biopharma Inc., Healthcare stocks n...

Principia Biopharma (NASDAQ: PRNB ): Q4 GAAP EPS of -$0.80 misses by $0.02 . More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced financial results for the fourth quarter and full year ended De...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

In our original report on Principia Biopharma, we emphasized that BTK inhibitors have failed over and over in autoimmune diseases, which we attribute to a basic problem with their mechanism of action: their main effect is to impair the production of new B-cell lineages, leaving the previou...